AstraZeneca’s Farxiga Flies Across $1bn Barrier

Stellar Sales Of SGLT2 Inhibitor

First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.

Pascal Soriot
Pascal Soriot • Source: AstraZeneca

While much of the focus on AstraZeneca PLC's first-quarter figures was on its COVID-19 products Vaxzevria and Evusheld, the drug that caught the eye was Farxiga, hitting the $1bn sales mark and exceeding analyst forecasts by some distance.

Speaking to Scrip as AstraZeneca unveiled a healthy set of financials for the first quarter which saw sales jump 56%...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip